Protein carbamylation links inflammation, smoking, uremia and atherogenesis

Nature Medicine

Volumn 13, Issue 10, 2007, Pages 1176-1184

  Wang, Zeneng ^a   Nicholls, Stephen J ^a   Rodriguez, E Rene ^a   Kummu, Outi ^b   Hörkkö, Sohvi ^b   Barnard, John ^a   Reynolds, Wanda F ^c   Topol, Eric J ^a,d   DiDonato, Joseph A ^a   Hazen, Stanley L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF OULU   (Finland)

^c SIDNEY KIMMEL CANCER CENTER   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYANIC ACID; HOMOCITRULLINE; LIGAND; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; PROTEIN; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR A1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD LEVEL; CARBAMOYLATION; CARDIOVASCULAR RISK; CLINICAL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FOAM CELL; HEART DEATH; HEART INFARCTION; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; SMOKING; STROKE; UREMIA;

ANIMALS; ATHEROSCLEROSIS; BLOOD PROTEINS; CARBAMATES; CHOLESTEROL; CITRULLINE; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; CYANATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOAM CELLS; HUMANS; INFLAMMATION; JURKAT CELLS; LIPOPROTEINS, LDL; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; OXIDATION-REDUCTION; PEROXIDASE; PREDICTIVE VALUE OF TESTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, LDL; SCAVENGER RECEPTORS, CLASS A; SMOKING; UREMIA;

EID: 34948834705     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1637     Document Type: Article

References (47)

1. Erill, S., Calvo, R. & Carlos, R. Plasma protein carbamylation and decreased acidic drug protein binding in uremia. Clin. Pharmacol. Ther. 27, 612-618 (1980).
2. Fluckiger, R., Harmon, W., Meier, W., Loo, S. & Gabbay, K.H. Hemoglobin carbamylation in uremia. N. Engl. J. Med. 304, 823-827 (1981).
3. Hörkkö, S., Huttunen, K., Kervinen, K. & Kesaniemi, Y.A. Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein. Eur. J. Clin. Invest. 24, 105-113 (1994).
4. Kraus, L.M. & Kraus, A.P., Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int. Suppl. 78, S102-S107 (2001).
5. Stark, G.R., Stein, W.H. & Moore, S. Reactions of the cyanante present in aqueous urea with amino acids and proteins. J. Biol. Chem. 235, 3177-3181 (1960).
6. Bobb, D. & Hofstee, B.H. Gel isoelectric focusing for following the successive carbamylations of amino groups in chymotrypsinogen A. Anal. Biochem. 40, 209-217 (1971).
7. Stark, G.R. Reactions of cyanate with functional groups of proteins. II. Formation, decomposition, and properties of N-carbamylimidazole. Biochemistry 4, 588-595 (1965).
8. Stim, J. et al. Factors determining hemoglobin carbamylation in renal failure. Kidney Int. 48, 1605-1610 (1995).
9. Lhotta, K., Schlogl, A., Uring-Lambert, B., Kronenberg, F. & Konig, P. Complement C4 phenotypes in patients with end-stage renal disease. Nephron 72, 442-446 (1996).
10. Mun, K.C. & Golper, T.A. Impaired biological activity of erythropoietin by cyanate carbamylation. Blood Purif. 18, 13-17 (2000).
11. Ok, E., Basnakian, A.G., Apostolov, E.O., Barri, Y.M. & Shah, S.V. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int. 68, 173-178 (2005).
12. Nicholls, S.J. & Hazen, S.L. Myeloperoxidase and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 25, 1102-1111 (2005).
13. Hazen, S.L. & Heinecke, J.W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99, 2075-2081 (1997).
14. Podrez, E.A., Schmitt, D., Hoff, H.F. & Hazen, S.L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 103, 1547-1560 (1999).
15. Zhang, R. et al. Association between myeloperoxidase levels and risk of coronary artery disease. J. Am. Med. Assoc. 286, 2136-2142 (2001).
16. Brennan, M.L. et al. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349, 1595-1604 (2003).
17. Asselbergs, F.W., Reynolds, W.F., Cohen-Tervaert, J.W., Jessurun, G.A. & Tio, R.A. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am. J. Med. 116, 429-430 (2004).
18. McMillen, T.S., Heinecke, J.W. & LeBoeuf, R.C. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 111, 2798-2804 (2005).
19. Castellani, L.W., Chang, J.J., Wang, X., Lusis, A.J. & Reynolds, W.F. Transgenic mice express human MPO -463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463G males. J. Lipid Res. 47, 1366-1377 (2006).
20. Abu-Soud, H.M. & Hazen, S.L. Nitric oxide is a physiological substrate for mammalian peroxidases. J. Biol. Chem. 275, 37524-37532 (2000).
21. Eiserich, J.P. et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296, 2391-2394 (2002).
22. Baldus, S. et al. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic. Biol. Med. 37, 902-911 (2004).
23. Vita, J.A. et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110, 1134-1139 (2004).
24. Zheng, L. et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114, 529-541 (2004).
25. Shao, B. et al. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J. Biol. Chem. 280, 5983-5993 (2005).
26. Zheng, L. et al. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J. Biol. Chem. 280, 38-47 (2005).
27. Wu, Z. et al. The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat. Struct. Mol. Biol. 14, 861-868 (2007).
28. Wever, R., Kast, W.M., Kasinoedin, J.H. & Boelens, R. The peroxidation of thiocyanate catalysed by myeloperoxidase and lactoperoxidase. Biochim. Biophys. Acta 709, 212-219 (1982).
29. Olea, F. & Parras, P. Determination of serum levels of dietary thiocyanate. J. Anal. Toxicol. 16, 258-260 (1992).
30. Husgafvel-Pursiainen, K., Sorsa, M., Engstrom, K. & Einisto, P. Passive smoking at work: biochemical and biological measures of exposure to environmental tobacco smoke. Int. Arch. Occup. Environ. Health 59, 337-345 (1987).
31. van Dalen, C.J., Whitehouse, M.W., Winterbourn, C.C. & Kettle, A.J. Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem. J. 327, 487-492 (1997).
32. Kersten, H.W., Moorer, W.R. & Wever, R. Thiocyanate as a cofactor in myeloperoxidase activity against Streptococcus mutans. J. Dent. Res. 60, 831-837 (1981).
33. Arlandson, M. et al. Eosinophil peroxidase oxidation of thiocyanate. Characterization of major reaction products and a potential sulfhydryl-targeted cytotoxicity system. J. Biol. Chem. 276, 215-224 (2001).
34. Stark, G.R. On the reversible reaction of cyanate with sulfhydryl groups and the determination Of NH2-terminal cysteine and cystine in proteins. J. Biol. Chem. 239, 1411-1414 (1964).
35. 2-terminal residues in proteins. J. Biol. Chem. 238, 214-226 (1963).
36. Brennan, M.L. et al. A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J. Biol. Chem. 277, 17415-17427 (2002).
37. Zhang, R. et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J. Biol. Chem. 277, 46116-46122 (2002).
38. Kumar, A.P., Piedrafita, F.J. & Reynolds, W.F. Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. J. Biol. Chem. 279, 8300-8315 (2004).
39. Thukkani, A.K. et al. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation 108, 3128-3133 (2003).
40. Hörkkö, S., Savolainen, M.J., Kervinen, K. & Kesaniemi, Y.A. Carbamylation-induced alterations in low-density lipoprotein metabolism. Kidney Int. 41, 1175-1181 (1992).
41. Sugiyama, S. et al. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler. Thromb. Vasc. Biol. 24, 1309-1314 (2004).
42. Yang, J., Cheng, Y., Ji, R. & Zhang, C. A novel model of inflammatory neointima formation reveals a potential role of myeloperoxidase in neointimal hyperplasia. Am. J. Physiol. Heart Circ. Physiol. 291, H3087-H3093 (2006).
43. Hill, P., Haley, N.J. & Wynder, E.L. Cigarette smoking: carboxyhemoglobin, plasma nicotine, cotinine and thiocyanate vs self-reported smoking data and cardiovascular disease. J. Chronic Dis. 36, 439-449 (1983).
44. Markwell, M.A., Haas, S.M., Bieber, L.L. & Tolbert, N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87, 206-210 (1978).
45. Podrez, E.A. et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J. Clin. Invest. 105, 1095-1108 (2000).
46. Anderson, K.M., Odell, P.M., Wilson, P.W. & Kannel, W.B. Cardiovascular disease risk profiles. Am. Heart J. 121, 293-298 (1991).
47. Stoves, J., Lindley, E.J., Barnfield, M.C., Burniston, M.T. & Newstead, C.G. MDRD equation estimates of glomerular filtration rate in potential living kidney donors and renal transplant recipients with impaired graft function. Nephrol. Dial. Transplant. 17, 2036-2037 (2002).